Date: 2016-05-24 12:17:21Medical research Food and Drug Administration Clinical pharmacology Pharmaceutical industry Expanded access Clinical research Investigational New Drug | | CMX001 is a Potential Treatment for Adenovirus Infection: Preliminary Antiviral Activity Results from an Open-label, Expanded Access Study of CMX001 for the Treatment of Serious or Life-threatening Diseases Caused by DoAdd to Reading ListSource URL: www.reaganudall.orgDownload Document from Source Website File Size: 537,83 KBShare Document on Facebook
|